With the installation of more than 600 CyberKnife robotic radiosurgery and TomoTherapy systems in 33 countries, radiation therapy firm Accuray this week told investors in San Francisco that there are additional opportunities for future growth.
In a presentation at the annual J.P. Morgan Healthcare Conference, Accuray noted that as its older CyberKnife and TomoTherapy systems reach the end of their life cycles, it expects to replace these units and older, pre-existing linear accelerators at other healthcare facilities.
As the installed base grows, Accuray also expects to generate recurring revenue through service contracts.
